Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.84 | N/A | +13.33% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.84 | N/A | +13.33% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative therapies.
Bristol Myers Squibb's strong EPS performance indicates effective cost management and operational efficiency. The stock's positive reaction of 3.53% suggests investor confidence in the company's current trajectory, despite the lack of revenue data and future guidance. Investors may view the EPS beat as a sign of resilience in a competitive market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Apr 24, 2017